Share

August 13, 2019; 93 (7) Editorial

Multiple system atrophy and myoclonus

A morphologic marker in the spinal cord?

Lorraine V. Kalia, Kurt A. Jellinger
First published August 12, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007941
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
294

Share

Article Information

vol. 93 no. 7 287-288
DOI: 
https://doi.org/10.1212/WNL.0000000000007941
PubMed: 
31405931
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published August 12, 2019.
Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Lorraine V. Kalia, MD, PhD, FRCPC and
    2. Kurt A. Jellinger, MD, PhD
  1. Lorraine V. Kalia, MD, PhD, FRCPC and
    2. Scientific Advisory Boards:

    1. (1) NINDS Parkinson's Disease Biospecimen Review Access Committee (PD BRAC)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Allergen Inc., funding for travel to attend conference (2) British Pharmacological Society, funding for travel to speak at conference (3) Canadian Institutes of Health Research, funding for travel to speak at conference (4) Canadian Neurological Sciences Federation, funding for travel to speak at conference (5) International Association of Parkinsonism and Related Disorders, funding for travel to speak at conference (6) Michael J. Fox Foundation for Parkinson?s Research, funding for travel to speak at conference (7) Shire, honorarium to speak at conference (8) University of Alberta, funding to speak at conference (9) University of California Irvine, honorarium to speak at conference

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Alion Pharmaceuticals Inc. (2) ApoPharma Inc.

    Research Support, Government Entities:

    1. (1) Canadian Institutes of Health Research, Principal Investigator, 2015-2023 (2) Ontario Brain Institute, Principal Investigator, 2018- 2020 (3) Natural Sciences and Engineering Research Council of Canada, Principal Investigator, 2015-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) J. P. Bickell Foundation (2) Michael J. Fox Foundation for Parkinson?s Research (3) Parkinson Canada (4) Toronto General & Western Hospital Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Kurt A. Jellinger, MD, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Acta Neuropathol, executive editor, 1978-2004 (2)Acta Neuropathol, senior editor since 2005 (3)Neuropsychiatrie, editor (4)Clin Neuropathol, editor, 1982 (5)Acta Neurochir, advisory board (6)Neuropaediatrics, member of editorial board (7)Clinical Neuropathology, member of editorial board (8)Acta Neurochir (Wien), member of editorial board (9)Neurodegenerative Disorders, member of editorial board (10)Schweiz Arch Neurol Psychiatr, member of editorial board (11)J Neurol Sciences, member of editorial board (12)Neurodegeneration, member of editorial board (13)Brain Pathology, member of editorial board (14)J Neural Transm, member of editorial board (15)Parkinsonism Related Disorders, member of editorial board (16)Brain Tumor Pathology, member of editorial board (17)Exp Neurology, member of editorial board (18)J Alzheimer Disease, member of editorial board (19)Acta Neurol Scand, member of editorial board, 2005-2010 (20)J Molec Cell Pathol, member of editorial board (21)Medical Science Monitor, member of editorial board (22)Histology and Histopathology, member of editorial board (23)J Clin Neurol, member of editorial board (24)Neural Regen Res, member of editorial board (25)Int J Molec Sci, member of editorial board (26)Dement Geriatr Cogn Disord, member of editorial board, since 2009 (27)Section Editor in Chief Int J Molec Sciences, member of editorial board (28)Int. J Alzheimer's Dis, member of editorial board (29)J Pediatr Biochem, member of editorial board (30)Frontiers in Biosciences, member of editorial board, since 2009 (31)In J Clin Exp Med, member of editorial board, since 2010 (32)Neurol Regen Res, member of editorial board, since 2009 (33)Am J Neuroprotec Neuroregen, member of editorial board, since 2010 (34)J Molec Biomarkers, member of editorial board, since 2010 (35)Frontiers in Biosciences, member of editorial board, since 2010 (36)J Biolog Med, member of editorial board, since 2010 (37)Challenges, member of editorial board, since 2011

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Society for Support of Research in Experimental Neurology, Vienna, Austria

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Krembil Research Institute (L.V.K.) and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine (L.V.K.), Toronto Western Hospital, University Health Network; Division of Neurology, Department of Medicine (L.V.K.), and Tanz Centre for Research in Neurodegenerative Diseases (L.V.K.), University of Toronto, Canada; and Institute of Clinical Neurobiology (K.A.J.), Vienna, Austria.
  1. Correspondence
    Dr. Kalia lorraine.kalia{at}utoronto.ca
View Full Text

Article usage

Article usage: August 2019 to January 2021

AbstractFullPdfSource
Aug 20192235228Highwire
Sep 2019891018Highwire
Oct 20195566Highwire
Nov 20196345Highwire
Dec 201957012Highwire
Jan 202057316Highwire
Feb 202060514Highwire
Mar 202041212Highwire
Apr 202035016Highwire
May 202090010Highwire
Jun 2020166215Highwire
Jul 202044112Highwire
Aug 202048115Highwire
Sep 202055131Highwire
Oct 202055016Highwire
Nov 202055222Highwire
Dec 202066222Highwire
Jan 202175424Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me